To match that estimated rate, we repeatedly administered 500 ng doses of mCXCL10 solutions in PBS every other day over the 5 days of dosing Upon completion of the study, we observed significant tumor growth attenuation and a significant increase in CD8+ T‐cell trafficking in B16 melanoma flank tumors after a single dose of the hydrogels tethered to mCXCL10‐3azidoester, equivalent to the results observed in the soluble mCXCL10 condition that was administered multiple times (Figures 7b–d and S10). The gene discussed is CD8A; the disease is melanoma.